{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:40:49Z","timestamp":1791906049722,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jconrel.2022.04.024","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:04:01Z","timestamp":1651104241000},"page":"275-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Population pharmacokinetics and IVIVC for mesalazine enteric-coated tablets"],"prefix":"10.1016","volume":"346","author":[{"given":"Yufeng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siu Kwan","family":"Wo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.04.024_bb0005","first-page":"16","article-title":"Oral modified drug release solid dosage form with special reference to design; An overview","volume":"12","author":"Murugesan","year":"2020","journal-title":"Curr. Drug Res. Rev."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0010","first-page":"499","article-title":"Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs","volume":"4","author":"Yu","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0015","first-page":"14014","article-title":"Temperature-responsive multilayer films based on block copolymer-coated silica nanoparticles for long-term release of favipiravir","volume":"4","author":"Xu","year":"2021","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0020","first-page":"3687","article-title":"Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy","volume":"117","author":"Chen","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0025","first-page":"1725","article-title":"Investigating halloysite nanotubes as a potential platform for oral modified delivery of different BCS class drugs: characterization, optimization, and evaluation of drug release kinetics","volume":"16","author":"Husain","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.04.024_bb0030","first-page":"221","article-title":"MMX(R) Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis","volume":"71","author":"Yang","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2022.04.024_bb0035","first-page":"500","article-title":"Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease","volume":"38","author":"Brogden","year":"1989","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2022.04.024_bb0040","first-page":"632","article-title":"Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine","volume":"21","author":"van Hees","year":"1980","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2022.04.024_bb0045","first-page":"511","article-title":"Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man","volume":"25","author":"Fischer","year":"1983","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0050","first-page":"1669","article-title":"Mesalazine for the treatment of inflammatory bowel disease","volume":"14","author":"Criscuoli","year":"2013","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0055","article-title":"Recent advances in mesalamine colonic delivery systems","volume":"6","author":"Bayan","year":"2020","journal-title":"Futur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0060","first-page":"1527","article-title":"Drug solubility in luminal fluids from different regions of the small and large intestine of humans","volume":"7","author":"Fadda","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0065","first-page":"196","article-title":"Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract","volume":"28","author":"Myers","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2022.04.024_bb0070","first-page":"211","article-title":"Dissolution of commercially available Mesalamine formulations at various pH levels","volume":"15","author":"Tenjarla","year":"2015","journal-title":"Drugs R D"},{"key":"10.1016\/j.jconrel.2022.04.024_bb0080","first-page":"514","article-title":"Liver and gut mucosa acetylation of mesalazine in healthy volunteers","volume":"38","author":"Vree","year":"2000","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0085","first-page":"93","article-title":"Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers","volume":"11","author":"Jakate","year":"2019","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0090","author":"WHO"},{"key":"10.1016\/j.jconrel.2022.04.024_bb0095","first-page":"1207","article-title":"Review article: oral, modified-release mesalazine formulations--proprietary versus generic","volume":"17","author":"Forbes","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0100","author":"FDA"},{"key":"10.1016\/j.jconrel.2022.04.024_bb0105","author":"FDA"},{"key":"10.1016\/j.jconrel.2022.04.024_bb0110","first-page":"1089","article-title":"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers","volume":"19","author":"Sandborn","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0115","first-page":"749","article-title":"Pharmacokinetics and safety of single and multiple doses of Asacol tablets in Japanese healthy volunteers","volume":"26","author":"Ito","year":"2009","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0120","first-page":"395","article-title":"Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation","volume":"17","author":"Brunner","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0125","first-page":"137","article-title":"5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers","volume":"23","author":"Brunner","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0130","first-page":"21","article-title":"Model-based drug development","volume":"82","author":"Lalonde","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0135","first-page":"169","article-title":"In vitro - in vivo correlation: from theory to applications","volume":"9","author":"Emami","year":"2006","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0140","author":"FDA"},{"key":"10.1016\/j.jconrel.2022.04.024_bb0145","first-page":"1","article-title":"A survey on IVIVC\/IVIVR development in the pharmaceutical industry - past experience and current perspectives","volume":"102","author":"Nguyen","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0150","first-page":"19","article-title":"PBPK absorption modeling: establishing the in vitro-in vivo link-industry perspective","volume":"21","author":"Stillhart","year":"2019","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0155","author":"FDA"},{"key":"10.1016\/j.jconrel.2022.04.024_bb0160","first-page":"38","article-title":"Screening of bioequivalent extended-release formulations for metformin by principal component analysis and convolution-based IVIVC approach","volume":"23","author":"Zhang","year":"2021","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0165","first-page":"1735","article-title":"Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation","volume":"36","author":"Bondesen","year":"1991","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0170","article-title":"Deconvolution analysis by non-linear regression using a convolution-based model: comparison of nonparametric and parametric approaches","volume":"22","author":"Gomeni","year":"2019","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0175","first-page":"711","article-title":"Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies","volume":"34","author":"Savic","year":"2007","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0180","author":"EMA"},{"key":"10.1016\/j.jconrel.2022.04.024_bb0185","first-page":"1035","article-title":"Measurement of gastrointestinal pH profiles in normal ambulant human subjects","volume":"29","author":"Evans","year":"1988","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2022.04.024_bb0190","first-page":"131","article-title":"Eudragit: a technology evaluation","volume":"10","author":"Thakral","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0195","first-page":"123","article-title":"Modeling and comparison of dissolution profiles","volume":"13","author":"Costa","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0200","author":"FDA"},{"key":"10.1016\/j.jconrel.2022.04.024_bb0205","author":"FDA"},{"key":"10.1016\/j.jconrel.2022.04.024_bb0210","first-page":"155","article-title":"Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies","volume":"65","author":"Mishra","year":"2010","journal-title":"Pharmazie"},{"key":"10.1016\/j.jconrel.2022.04.024_bb0215","first-page":"1607","article-title":"Development of an extended-release formulation for Apremilast and a level a in vitro-in vivo correlation study in beagle dogs","volume":"64","author":"Tang","year":"2016","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.jconrel.2022.04.024_bb0220","first-page":"737","article-title":"A new in vitro\/in vivo kinetic correlation method for nitrofurantoin matrix tablet formulations","volume":"26","author":"Ertan","year":"2000","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0225","first-page":"97","article-title":"A general framework for assessing in vitro\/in vivo correlation as a tool for maximizing the benefit-risk ratio of a treatment using a convolution-based modeling approach","volume":"8","author":"Gomeni","year":"2019","journal-title":"Cpt-Pharmacomet Syst."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0230","first-page":"495","article-title":"Direct, differential-equation-based in-vitro-in-vivo correlation (IVIVC) method","volume":"55","author":"Buchwald","year":"2003","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0235","first-page":"317","article-title":"A population approach to in vitro-in vivo correlation modelling for compounds with nonlinear kinetics","volume":"38","author":"Gaynor","year":"2011","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0240","article-title":"Comparison of alternative population modeling approaches for implementing a level a IVIVC and for assessing the time-scaling factor using deconvolution and convolution-based methods","volume":"22","author":"Gomeni","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0245","first-page":"2138","article-title":"Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption","volume":"52","author":"Wilkins","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2022.04.024_bb0250","author":"Boudriau"},{"key":"10.1016\/j.jconrel.2022.04.024_bb0255","first-page":"1073","article-title":"Polymorphisms of N-acetyltransferase genes","volume":"22","author":"Grant","year":"1992","journal-title":"Xenobiotica"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922002206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922002206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:24:44Z","timestamp":1759163084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922002206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":50,"alternative-id":["S0168365922002206"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.04.024","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics and IVIVC for mesalazine enteric-coated tablets","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.04.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}